CiplaQCIL manufacture malaria drug in response to government’s Covid-19 request

By May 10, 2020August 5th, 2020Company News

With the global outbreak of the coronavirus (COVID-19) pandemic, the World Health Organization (WHO) is conducting a global clinical trial, called SOLIDARITY, to identify possible treatment options for this contagious disease[1]. The malaria treatment, hydroxychloroquine is one of the four drugs being used in the trial. The Ministry of Health in Uganda has proposed using hydroxychloroquine to treat COVID-19 patients in the country[2]. Hydroxychloroquine is also currently used to treat autoimmune diseases, such as systemic lupus erythematosus and rheumatoid arthritis[3].

CiplaQCIL CEO, Nevin J Bradford

Uganda currently has identified 248 COVID-19 positive cases[4]. There have been no deaths identified as a result of the virus in the country and 55 patients have recovered4. Hydroxychloroquine was used to treat these patients. Clarity on whether this medication had a positive impact on these patients will only be known once the SOLIDARITY trial is complete.

As part of Uganda’s COVID-19 response, His Excellency President Yoweri Museveni, President of Uganda, called Indian Prime Minister Narendra Modi, to reach an agreement where India will expedite export 750kgs of the hydroxychloroquine active pharmaceutical ingredient (API) to CiplaQCIL to enable local production of the drug[5]. The API is currently being exported and CiplaQCIL will start the manufacturing process within the next few days.

CiplaQCIL has already committed to locally manufacture hydroxychloroquine in line with its “Africa for Africa” strategy to meet the Ministry of Health’s and Ugandan government’s demand for this medicine. CEO of CiplaQCIL, Nevin Bradford, said: “Caring for life is our utmost priority. We are gearing up to fast-track production of this drug to meet the estimated requirements. Naturally, we do earnestly hope that the medication will not be required as Uganda has implemented restrictions such as lockdown and a night curfew to help flatten the curve. In that case, the medicine will be used for its initially approved indications.”

CiplaQCIL is known for producing quality, affordable medication, and thereby ensuring that people have access to lifesaving medicine.

[1] Kupferschmidt, K. and Cohen, J. WHO launches global megatrial of the four most promising coronavirus treatments. ScienceMag (2020)(https://www.sciencemag.org/news/2020/03/who-launches-global-megatrial-four-most-promising-coronavirus-treatments
[2] Uganda picks hydroxychloroquine to treat COVID-19 patients. Available at https://www.independent.co.ug/uganda-using-hydroxychloroquine-to-treat-covid-19-patients/
[3] Liu, J., et al. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discovery, 6:16, 2-4 {“type”:”block”,”srcIndex”:1,”srcClientId”:”230bd546-438d-45c7-a25a-fa2ecb7e9551″,”srcRootClientId”:””}(2020)
[4] Worldometer: Coronavirus on 19 May: https://www.worldometers.info/coronavirus/
[5] https://www.softpower.ug/india-to-support-uganda-to-locally-manufacture-hydroxychloroquine-protective-gear/